Quote this publication Share Print

LAMICTAL-LAMICSTART

-
Opinions on drugs - Posted on Jun 13 2012

Reason for request

Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use in the extension of indication “”Monotherapy treatment for typical absence seizures in children and adolescents aged 2 to 12 years”.

-


Clinical Benefit

Substantial

The actual benefit of these medicinal products is substantial.


Clinical Added Value

no clinical added value

LAMICTAL and LAMICSTART do not provide an improvement in actual benefit (IAB V) in the management by monotherapy of typical absence seizures in children and adolescents aged 2 to 12 years.


Contact Us

Évaluation des médicaments

See also